Creating Transformative Medicines to Improve Patients’ Lives Program Updates December 2, 2024 Exhibit 99.2

Forward-Looking Statements and Disclaimers This presentation includes certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements regarding Janux Therapeutics, Inc. (the “Company”). These forward-looking statements include, but are not limited to, those regarding the Company’s ability to bring new treatments to patients in need, the progress and expected timing of the Company’s drug development programs, and clinical development plans and timelines and estimates regarding the Company’s expenses and capital requirements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that the Company may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Also, interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change following more comprehensive reviews of the data, as patient enrollment continues, and as more patient data become available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations. In light of these risks, uncertainties, contingencies and assumptions, the events or circumstances referred to in the forward-looking statements may not occur. For a further list and description of the risks and uncertainties that the Company faces, please refer to the Company’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products. This presentation concerns therapeutic product candidates that are in preclinical and clinical development and which have not yet been approved for marketing by the U.S. Food and Drug Administration. They are currently limited by federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated. Certain data in this presentation are based on cross-study comparisons and are not based on any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities or differences. Actual results may differ from these comparisons. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies.

Janux – multiple near-term high value opportunities in CD3 TCE targets JANX007 Pipeline and Platform Cash Position *As of Sept 30, 2024, includes cash and cash equivalents JANX008 PSMAxCD3-TRACTr to treat mCRPC demonstrated substantial clinical activity Today’s update focuses upon efficacy and safety data supporting selection of two step dose regimens for pre-Pluvicto 2L and 3L Phase 1b studies EGFRxCD3-TRACTr providing entry point into multiple large indications Dose escalation ongoing Clinical data demonstrates TRACTr can potentially improve safety and efficacy compared to contemporary TCEs Multiple programs in development moving to clinical studies Robust cash position of $658M* to support program advancement and operating plan through 2027, including PSMAxCD3 and EGFRxCD3 Phase 1b expansion studies

Janux Tumor Activated T-Cell Engager (TRACTr) platform design principlesEach program is designed as a potent T-cell engager with reduced toxicity Emerging JANX007 clinical data demonstrates TRACTr platform can potentially improve both safety and efficacy compared to contemporary TCEs TRACTr Design Healthy Tissue Tumor Tissue Healthy Tissue Masks block activity against healthy tissues to reduce CRS and on-target, healthy tissue toxicity Tumor specific activation to maximize anti-tumor immune response TCE is rapidly cleared from healthy tissue to limit systemic toxicity

JANX007 clinical PK data continues to be consistent with TRACTr design principlesProlonged TRACTr exposure with minimal accumulation of activated TCE Systemic levels of activated TCE remain more than 100-fold lower than TRACTr across doses - Consistent with NHP safety studies and TRACTr design - 0.2/0.6/2 mg (single patient) 0.3/1/3 mg (single patient) 0.3/1.5/6 mg (single patient)

JANX007 Update Resetting the bar in prostate cancer

1L treatment: Enzalutamide Docetaxel Abiraterone 2L 3L+ Pluvicto + SOC Janux P1b will have readthrough into a potential multibillion dollar opportunity in 2L mCRPC JANX007 clinical development focusing upon pre-Pluvicto 2L and 3L settings PARPi combo 1L (80k) JANX007 Future Patient Opportunity Abi – 2.9 Doc - 6.8 8.7 27K Enza - 8.1 Doc - 4.4 Enza - 8.3 Abi - 5.6 1L treated pts: (US + EU5) 2L PFS: (months) 19K 20K 21K NA 6K Patients: (US + EU5) 3L PFS: (months) Deep and durable PSA declines coupled with a well tolerated safety profile supports development in early lines of treatment

0.1 mg C1 0.3 mg C2 0.05/0.1/0.3 mg C3 0.1/0.3/0.45 mg C4 0.1/0.3/1 mg C5 0.2/0.6/2 mg C6 0.3/1/3 mg C7 0.4/2/6 mg C8 0.3/1.5/6 mg C9 0.3/2/9 mg C10 JANX007 dose escalation schema and update focusQW cohorts prioritized to establish safety and efficacy profiles QW Dose Evaluations Current update cohort focus (n = 16)* February 2024 update cohort focus Ongoing Dose Evaluations QW 0.3/2/12 mg Q2W backfill cohorts with ≥3 mg target dose Male ≥18 years of age at the time of signing informed consent Histologically or cytologically confirmed adenocarcinoma of the prostate mCRPC that progressed after ≥ 1 novel anti-androgen therapy and ≥ 1 taxane containing regimen. Participants that refused a taxane or are medically unsuitable to receive a taxane are eligible Adequate organ function Patients not selected for PSMA expression Primary Safety Tolerability RP2D Secondary PSA response (PSA50, PSA90) Radiographic response Objectives Eligibility Criteria Data cutoff: November 15, 2024; *Excludes patients previously exposed to Pluvicto

JANX007 patient characteristicsHeavily pre-treated patients with a median of 4 prior lines of therapy *Number or prior lines of therapy does not include androgen deprivation therapy Characteristic Patients with target dose ≥2 mg QW n=16 Median age, years (range) 71.5 (54 – 79) Race, white / black / not reported, % 88 / 6 / 6 ECOG PS 0 / 1, n (%) 7 (44) / 9 (56) PSMA positive at baseline, n (%) 16 (100) Number of prior lines of therapy for mCRPC*, median (range) 4 (1 – 8) ≥ 4 prior lines, n (%) 9 (56) Prior systemic therapy, n (%) AR inhibitor Docetaxel PARP inhibitor Cabazitaxel PSMA-targeting radioligand therapy (RLT) 16 (100) 10 (63) 2 (13) 2 (13) 0 (0) Bone metastases, n (%) 15 (94) Lymph node metastases, n (%) 11 (69) Visceral metastases, n (%) 3 (19) Lung, n (%) Liver, n (%) Adrenal, n (%) 2 (13) 1 (6) 1 (6) Baseline PSA, ng/mL, median (range) 80.9 (1.03 – 1991.6)

JANX007 highly competitive clinical data profile supports development in early lines of therapy Resistance Driver Activity Encouraging Anti-Tumor Activity Patients with ≥90% PSA reduction PSA90: 17%  63% PSA99: 0%  31% PSA declines thru 12wks ≥PSA50 at 12-weeks: NE  75% ≥PSA90 at 12-weeks: NE  50% AR mutants, variant-7, amplifications; BRCA1/2, PI3K, PTEN, TP53 PSA50 100%, PSA90 54% ORR†: DCR†: Deepening PSA Declines* Improved PSA Durability* Well-Tolerated CRS and TRAEs primarily limited to Cycle 1 and lower grades MTD has not been reached Patients with ≥50% PSA reduction Feb 2024: Dec 2024: Increased Response Rate* *February 2024 vs December 2024 updates; †Includes confirmed and unconfirmed 83% 100% 63% 50%

Deep PSA declines coupled with predictable, transient and easily managed CRS in 5L ptsResponse rate not impacted by prior therapies Deep PSA declines in heavily treated 5L patient population regardless of prior taxane and ARPI use QW Dose Cohorts 0.2/0.6/2 mg 0.3/1/3 mg 0.4/2/6 mg 0.3/1.5/6 mg 0.3/2/9 mg Best PSA % Change from Baseline JANX007 drove rapid and deep PSA declines 100% PSA50, 63% PSA90, 31% PSA99 Competitor PSA50/90 levels* 48% / 28% with 3L Pluvicto + SOC 50% / 28% with 4L AMG509 High PSA response rate regardless of prior taxane/ARPI treatment CRS was predictable, transient and easily managed Primarily occurs in cycle 1 Onset and duration in day 1 Patient number 039 045 042 049 020 040 022 043 035 017 031 044 046 048 038 047 Cycle 1 CRS Prior Taxane(s) 1 1 1 - 1 2 1 - - 2 2 - - - 1 1 Prior ARPI(s) 1 3 1 1 2 2 2 5 2 2 2 3 2 1 3 3 # prior lines† 2 4 2 3 5 8 4 5 3 5 4 4 3 1 4 3 Dose-1 Dose-2 Target % CRS by grade in cycle 1 Grade 1 Grade 2 PSA99 PSA50 PSA70 PSA90 †Excludes ADT; *This information is provided for illustrative purposes only and is not a head-to-head comparison

Deep PSA responses irrespective of resistance driver aberration statusJANX007 retained full activity against wild-type and resistant patient populations JANX007 demonstrated robust activity against wildtype and major drug resistance driver mutations/aberrations QW Dose Cohorts 0.2/0.6/2 mg 0.3/1/3 mg 0.4/2/6 mg 0.3/1.5/6 mg 0.3/2/9 mg Patients harboring key resistance drivers (n = 13) 100% PSA50, 54% PSA90, 23% PSA99 WT patients (n = 3) 100% PSA90, 67% PSA99 Provides potential opportunity to: Treat broader patient segments Combine with approved drugs 2L Incidence† 12K AR-mutant L,T L,H L T L,T 18K AR-V7 + + + + + + + + + 18K AR-amp + + + + 17K *HRRm + + + + + + + 12K Other + + + + + + + + + AR-mutants L: L702H; H: H875Y; T: T878A/S Other p53, MYC, PI3K, PTEN, TMPRSS2 Best PSA % Change from Baseline PSA50 PSA70 PSA90 *Mutations within either of 13 HRR genes in Foundation One Panel; †US/EU incidence

Encouraging anti-tumor responses in RECIST evaluable 5L patients supports progression to Ph1b studies Early indication of significant anti-tumor activity 5/8 patients had tumor reductions from baseline 4/8 patients had ≥30% tumor reductions from baseline 50% ORR†, 63% DCR† Competitor results** 30% ORR with 3L Pluvicto + SOC 20% ORR with 4L AMG509 Patient number 045 017 049 035* 043 046* 022 020* Best response PD PD PD SD uPR uPR uPR cPR PSA at 12wks NA PSA90 NA PSA90 PSA50 PSA50 PSA90 PSA50 QW Dose Cohorts 0.2/0.6/2 mg 0.3/1/3 mg 0.4/2/6 mg 0.3/1.5/6 mg 0.3/2/9 mg *Treatment ongoing; †Includes confirmed and unconfirmed; **This information is provided for illustrative purposes only and is not a head-to-head comparison Confirmed PSA90 and PSMA-negative disease by CT/PET scan at time of progression

Encouraging early signs of durability with JANX007 Encouraging depth and durability of PSA declines supports development in earlier lines of therapy Deep and durable PSA declines in both measurable and bone only disease ≥ PSA50 at 12wks = 75% ≥ PSA90 at 12wks = 50% Encouraging early RECIST anti-tumor responses ORR† = 50% *Non-optimal treatment guidance; †Includes confirmed and unconfirmed PSMA(-) NEPC progression by biopsy RECIST Legend RECIST Evaluable Non-RECIST Evaluable RECIST PR RECIST SD PSA ≥ 50% - <90% PSA ≥ 90% PSA ≥ 99% On-Treatment PSA decline at 6 wk intervals PSA responses over time % PSA Change (from baseline) Weeks Optimal guidance Non-optimal guidance

Treatment guidance optimization and target dose escalation JANX007 exhibited predictable CRS onset and duration that rapidly responded to treatment < 24h Treatment with steroids beyond the resolution of CRS may negatively impact efficacy (red curves) New guidance provides opportunity to further improve responses Optimized dosing guidance and increased target dose results provide attractive path forward Target Dose 2 mg 3 mg 6 mg 9 mg Impact of modified guidance on PSA declines Weeks Weeks % PSA Change (from baseline) % PSA Change (from baseline) PSA durability is target dose dependent (median PSA*) Higher target doses are associated with more durable PSA responses Results are consistent with hypothesis that target dose is primary determinant of a durable response *Median PSA response by target dose (includes interpolated values)

Potential impact of treatment guidance optimization Improved treatment guidance provides an opportunity to further improve JANX007 responses QW Dose Cohorts 0.2/0.6/2 mg 0.3/1/3 mg 0.4/2/6 mg 0.3/1.5/6 mg 0.3/2/9 mg *Non-optimal guidance

JANX007 was well tolerated with a predictable safety profile CRS and TRAEs have been transient and predominantly occurred in cycle 1 Majority of TRAEs occur in Cycle 1 Highest event incidence after step 1 dose CRS events in C2+ are infrequent and primarily associated with intra-patient escalation and/or extended treatment delays *CRS mitigation non-conformance: in a single patient JANX007 was administered in Cycle 5 without appropriate CRS mitigation following an extended dose delay (rabies exposure) leading to a G3 CRS event. Subject has received multiple doses since the event with no recurrence of CRS. Pts evaluable at study cycle (8 ongoing) All TRAEs in ≥ 15% of patients Event Cycle 1 Cycle 2 Cycle 3+ % TRAEs 71% 19% 10% % of all ≥ G3 events 74% 19% 7% * All TRAEs in ≥ 15% of patients

Predictable safety profile in patients treated with weekly target dose ≥2 mg Majority of TRAEs were transient, predictable and known to be associated with CRS *Transient and asymptomatic AST/ALT elevations **G3 anemia reported in 2 patients with G1/2 at baseline Preferred Term TRAEs (max grade) in ≥ 15% of patients (n=16) Grade 1 Grade 2 Grade ≥3 All Grades Cytokine release syndrome 6 (38) 9 (56) 1 (6) 16 (100) ALT increased* 6 (38) 3 (19) 3 (19) 12 (75) AST increased* 5 (31) 1 (6) 6 (38) 12 (75) Diarrhea 4 (25) 5 (31) 2 (13) 11 (69) Vomiting 1 (6) 10 (63) 0 11 (69) Fatigue 4 (25) 5 (31) 1 (6) 10 (63) Dysgeusia 8 (50) 1 (6) 0 9 (56) Nausea 2 (13) 7 (44) 0 9 (56) Rash 4 (25) 5 (31) 0 9 (56) Hypophosphatemia 3 (19) 5 (31) 1 (6) 9 (56) Chills 4 (25) 4 (25) 0 8 (50) Hypoacusis 4 (25) 1 (6) 1 (6) 6 (38) Dry mouth 5 (31) 0 0 5 (31) Headache 4 (25) 1 (6) 0 5 (31) Preferred Term TRAEs (max grade) in ≥ 15% of patients (n=16) Grade 1 Grade 2 Grade ≥3 All Grades Anemia** 1 (6) 1 (6) 2 (13) 4 (25) Arthralgia 1 (6) 3 (19) 0 4 (25) Blood bilirubin increased 0 3 (19) 1 (6) 4 (25) Decreased appetite 2 (13) 2 (13) 0 4 (25) Myalgia 2 (13) 2 (13) 0 4 (25) Platelet count decreased 3 (19) 0 1 (6) 4 (25) Blood alk phos increased 2 (13) 0 1 (6) 3 (19) Blood LDH increased 3 (19) 0 0 3 (19) Hypoalbuminemia 2 (13) 1 (6) 0 3 (19) Hypotension 1 (6) 2 (13) 0 3 (19) INR increased 3 (19) 0 0 3 (19) Oedema peripheral 3 (19) 0 0 3 (19) Pruritus 1 (6) 2 (13) 0 3 (19) CRS graded by ASTCT 2019 criteria; all non-CRS TRAEs assessed per NCI-CTCAE v5.0

Pluvicto VISION study correlated PSA declines up to 12 weeks with rPFS and OS JANX007 high rate of PSA50 and PSA90 declines at 12 weeks supports opportunity to achieve meaningful PFS/OS A high percentage of JANX007 treated-patients maintained PSA declines ≥PSA50 and PSA90 at 12 weeks and supports an anticipated survival benefit PSA increase ≥0 to 50% decline ≥50 to 90% decline ≥90% decline 12wk PSA Range JANX007 (5L) Pluvicto + SOC (3L) Characteristic % pts % pts rPFS mOS PSA increase 6% 29% 5.8 9.8 ≥0 to <50% 0% 17% 8.7 14.0 ≥50 to <90% 25% 28% 11.3 18.3 >90% 50% 15% 20.3 NE Pluvicto’s rPFS by PSA decline at 12 weeks Armstrong, 2024; Information provided above is for illustrative purposes only and is not a head-to-head comparison Encouraging 12-week PSA durability with JANX007

Characteristic Median Tx line mPFS ORR Best PSA decline ≥ 50% Best PSA decline ≥ 90% ≥ PSA50 at 12wks** ≥ PSA90 at 12wks** JANX007 (≥ 2mg target) 5L 7.4 mo† (8/16 IP*) Pluvicto + SOC (7.4 GBq) 3L 8.7 mo (SOC 3.4 mo) AMG509 (≥ 0.75 mg target) 4L 7.8 mo NR ARX517 (≥ 2 mg) 5L NR NR NR JANX007 5L study demonstrated compelling PSA declines and durability JANX007 has the potential to change the treatment landscape in prostate cancer ††50% 100% 20% 25% 30% 48% 50% 52% 63% 28% 28% 26% 75% 43% 24% 50% 15% JANX007 - December 2024; Pluvicto - Sartor 2021, Armstrong 2024; AMG509 – Kelly, ESMO 2024; ARX517 - Shen, ESMO 2023 Information provided above is for illustrative purposes only and is not a head-to-head comparison *IP = in-progress; †Median PFS calculation limited by small sample size and duration of follow-up, ongoing patients censored at the time of cut-off; **PSA50(90) at 12wks / patients treated; ††Includes confirmed and unconfirmed

Current 2L mCRPC treatments highlight the opportunity for JANX007JANX007 5L results compare favorably to 2L drugs 1L Treatment 2L PFS (months) ORR PSA90 PSA50 Abi 2.9 Doc 6.8 Enza 8.1 Doc 4.4 Abi 5.6 Enza 8.3 Pluvicto 11.6 Enzalutamide Abiraterone Docataxel 0% 39% 12% 11% 14% 29% ARPi or Abi 13% 43% 8 58% 8 54% 8 48% 8 35% 8 29% 3% 12% 6% 1% 25% 8 33% 50% 5L Treatment PFS (months) ORR† PSA90 PSA50 7.4* 50% 63% 100% JANX007 25% †Includes confirmed and unconfirmed; *8/16 patients in-progress; Information provided above is for illustrative purposes only and is not a head-to-head comparison - Pluvicto in earlier line treatment (2L vs 3L) - PFS improved by 35-40% (12 vs 8.7 months) -

JANX007 is positioned to treat patients across the continuum of prostate cancer care Interventional therapy (nmCSPC, mCSPC) ~260K 1L mCRPC 3L+ mCRPC Hormonal therapy (nmCSPC, mCSPC) ~150K PFS:~33+mo OS: ~50mo JANX007 has the potential to address a broad segment of prostate cancer patients 2L mCRPC HSPC mCRPC US drug treated population AR dependency JANX007 Registrational clinical opportunities JANX007 monotherapy JANX007 monotherapy/combo JANX007 combo JANX007 monotherapy/combo JANX007 monotherapy/combo Current efficacy comparators Curative intent PFS:~16-20mo OS: ~19-36 mo PFS:~4-8mo OS: ~12-19 mo PFS:~4-9mo OS: ~11-15 mo JANX007 development opportunities Expected AR dependency Increasing loss of AR dependency ~35K ~25K ~8K

JANX007 – resetting the bar in prostate cancer Encouraging early data highlights potential for best-in-treatment opportunity Resistance Driver Activity Encouraging Anti-Tumor Activity PSA50: PSA90: AR mutants, variant-7, amplifications; BRCA1/2, PI3K, PTEN, TP53 PSA50 100%, PSA90 54% ORR†: DCR†: Deep PSA Declines Durable PSA Declines at 12wks Well-Tolerated CRS and TRAEs primarily limited to Cycle 1 and lower grades MTD has not been reached Patients with >50% PSA reduction High PSA Response Rate †Includes confirmed and unconfirmed 100% 63% 50% 75% 50% High rate of rapid, deep and durable responses, coupled with a predictable and well tolerated safety profile supports development in early lines of treatment PSA90: PSA99: 63% 31%

JANX007 – clinical plans and opportunities Large Opportunity Proof-of-Principle Forward Momentum JANX007’s unique MoA generated safety window potentially enables substantial efficacy in heavily treated patients Clinical development plan will focus upon pre-Pluvicto 2L and 3L patients Two QW step dose regimens identified for Phase 1b expansion studies directed at pre-Pluvicto 2L and 3L patients 0.3/1.5/6mg and 0.3/2/9 mg Ongoing Phase 1a evaluations: Q2W dosing >3 mg target dose to identify Q2W regimen for project Optimus evaluation QW 0.3/2/12 mg to evaluate safety window and determine if efficacy has plateaued Combination of efficacy and well tolerated safety profile positions JANX007 to move into early lines of therapy Positive data in 2L enzalutamide combo and 3L Optimus studies provides opportunity to move JANX007 into earlier lines of therapy

David Campbell, Ph.D.President and CEO 10955 Vista Sorrento Parkway San Diego, CA 92130 [email protected]